Oncology

Treating primary bone cancer: The potential of listeria-base...
In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Oncology

Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat...
At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
Newsletters and Deep Dive
digital magazine